Antibody for tumor and preparation method thereof
By providing the Thr52 site phosphorylation antigen peptide and antibodies of USP14, the problem of unknown regulatory effect of AMPK on USP14 phosphorylation is solved, and specific recognition of the phosphorylation of USP14 Thr52 site is achieved, providing a marker for tumor cell research tool.
Patent Information
- Application Number
- CN202411366280.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-29
- Publication Date
- 2024-11-15
AI Technical Summary
The regulatory effect of AMPK on USP14, the phosphorylation site and its specific impact on USP14 function have not been clarified, which has affected the research and development of tumor cells and the development of therapeutic strategies.
Provide a Thr52 site phosphorylated antigen peptide of the deubiquitinase USP14, phosphorylate the threonine site at the 52nd position of USP14 through AMPK kinase, and prepare antibodies that specifically recognize the phosphorylation of USP14 Thr52 site. Used to specifically recognize the phosphorylation of the Thr52 site of the USP14 protein.
The specific recognition of the phosphorylation of the Thr52 site of USP14 was achieved, and the marker tool for AMPK kinase activity and phosphorylation to modify USP14 was provided, which was used for the study of tumor cell function and molecular mechanisms.
Smart Images

Figure CN118956832A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to an antibody for tumors and a preparation method thereof. Background Art
[0002] AMPK kinase (AMP-activated protein kinase) is a key intracellular energy sensor that is widely involved in the regulation of cellular energy metabolism. Under normal physiological conditions, AMPK regulates metabolic pathways to maintain energy balance by sensing the energy status within the cell (such as the decrease in ATP and the increase in AMP). Its activation promotes energy generation and inhibits energy consumption to help cells cope with the challenge of energy deficiency.
[0003] However, recent studies have found that AMPK not only plays an important role in metabolic regulation, but also has a significant impact on tumor occurrence and development. Tumor cells often face extreme energy and nutrient supply conditions, which makes AMPK an important factor in regulating the adaptability of tumor cells. The effect of AMPK on tumorigenesis may be dual: in some cases, AMPK activation may inhibit tumor development, while in other cases, it may promote tumor cell growth and invasion. On the one hand, AMPK activation exhibits potential anti-tumor effects by inhibiting cell growth and proliferation, inducing cell apoptosis, and enhancing autophagy. For example, AMPK can inhibit the mTOR pathway, which is abnormally activated in many tumor types, thereby inhibiting the growth of tumor cells. On the other hand, AMPK activation may promote tumor adaptation and tolerance by changing the metabolic state of tumor cells. For example, AMPK activation may enhance the ability of tumor cells to survive under hypoxic or nutrient-deficient conditions, thereby supporting tumor growth and metastasis.
[0004] Ubiquitin-specific protease 14 (USP14) is an important deubiquitinase that is widely involved in the regulation of intracellular protein degradation and stability. USP14 regulates the degradation rate of proteins and the homeostasis of intracellular proteins by removing ubiquitin marks on target proteins during the deubiquitination process. This process is essential for a variety of biological functions of cells, including cell cycle regulation, signal transduction, apoptosis, and stress response. Studies have shown that USP14 can remove ubiquitin marks associated with tumor promotion and prolong the half-life of these proteins, thereby enhancing their function and promoting the proliferation and survival of tumor cells. USP14 may affect tumor angiogenesis, immune escape, and cell-to-cell interactions by regulating proteins associated with the tumor microenvironment. These effects help tumor cells adapt to and promote their growth and metastasis in a complex microenvironment.
[0005] Studying the specific mechanism of action of AMPK in tumor occurrence and development will help to deeply understand its complex role in tumor progression and provide new theoretical basis and practical guidance for the prevention and treatment of tumors in clinical practice. The role of USP14 in tumor occurrence and development is an important and complex research field. A deep understanding of the specific mechanism of USP14 in tumor biology will help to reveal the occurrence and progression of tumors and provide potential targets for the development of new therapeutic strategies. However, the phosphorylation regulation of AMPK on USP14, the phosphorylation sites and its specific effects on the function of USP14 have not yet been clarified. Summary of the invention
[0006] The first object of the present invention is to provide an antigenic peptide phosphorylated at the Thr52 site of the deubiquitinating enzyme USP14.
[0007] The second object of the present invention is to provide an application of the phosphorylated antigen peptide, specifically for preparing an antibody that specifically recognizes phosphorylated Thr52 of USP14.
[0008] The third object of the present invention is to provide an antibody that specifically recognizes the phosphorylated antigen at the Thr52 site of the deubiquitinating enzyme USP14.
[0009] The fourth object of the present invention is to provide a method for preparing the above-mentioned Thr52 phosphorylation antibody of the deubiquitinating enzyme USP14.
[0010] Another object of the present invention is to provide the use of the above antibody.
[0011] The purpose of the present invention is achieved through the following technical solutions: A phosphorylated antigenic peptide at Thr52 of USP14, characterized in that the active amino acid sequence of the antigenic peptide comprises a peptide segment of 14 amino acids, specifically KGG-pTLKDDDWGNIC, wherein threonine (T) is phosphorylated and is the 52nd threonine site of the USP14 protein.
[0012] Furthermore, the above phosphorylation is carried out by phosphorylating the 52nd threonine site of USP14 using AMPK kinase.
[0013] The invention provides an application of the phosphorylated antigen peptide at Thr52 of USP14 in the preparation of a preparation for specifically recognizing phosphorylation at Thr52 of USP14 protein.
[0014] An antibody that recognizes the phosphorylated Thr52 site of the above-mentioned USP14 is prepared by immunizing animals with the above-mentioned phosphorylated antigen peptide.
[0015] A method for preparing an antibody against the phosphorylation site Thr52 of USP14, comprising the following steps: (1) Using glutaraldehyde as a coupling agent, the synthesized USP14 phosphorylated antigen peptide was conjugated with the carrier protein abalone highly immunogenic protein (KLH) as an antigen; (2) Immunizing animals with the antigens in step (1) and collecting antiserum; (3) The antiserum is chromatographed and eluted to purify the antibody.
[0016] Furthermore, the animal immunization is to immunize two female New Zealand white rabbits with the antigen coupled in step (1), specifically, the first subcutaneous immunization is 1 mg, the second immunization is 2 weeks later, and the third immunization is 1 week later. After the immunization, blood is collected from the ear vein to test the titer. If the test is unqualified, the fourth immunization is continued, and blood is collected again for testing to obtain qualified antiserum.
[0017] Furthermore, in the purification step (3), the antiserum sample is coupled with NHS Focurose 4FF medium as a filler, and purified by chromatography. Specifically, the filler is added to the chromatography column, and then 5 times the volume of the balancing solution of the chromatography column is added for balancing, so that the medium is in the same buffer system as the coupled antibody, and the process is repeated 2-3 times. The sample is loaded into the equilibrated chromatography column, incubated for 5 minutes, the effluent is collected, and the loading is repeated 3 times. The balancing solution is composed of 0.15M NaCl and 20mM Na2HPO4, and the pH of the balancing solution is 7.0. The above-mentioned USP14 Thr52 phosphorylation antibody is used in the preparation of a preparation for detecting the phosphorylation of USP14 protein Thr52 site.
[0018] The present invention has the following technical effects: The Thr52 phosphorylated antigen peptide of USP14 provided by the present invention has an active amino acid sequence comprising 14 amino acid peptide segments, specifically KGG-pTLKDDDWGNIC, and the antibody prepared by animal immunization with the above antigen peptide has the ability to specifically recognize the Thr52 phosphorylation site of USP14, especially in tumor cells, it can specifically recognize the Thr52 phosphorylation of USP14, but not recognize the USP14 protein with Thr52 mutation, and has high phosphorylation specificity. The antibody can be used as a marker tool for AMPK kinase activity and phosphorylated modified USP14, and can be used for future research on the function and molecular mechanism of USP14 in tumor cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1: Immunoprecipitation detection diagram of AMPK regulating USP14 phosphorylation modification. A is the immunoprecipitation detection of AMPK on USP14 phosphorylation modification. B is the immunoprecipitation detection of the effect of AMPK kinase inactivation on USP14 phosphorylation.
[0020] Figure 2 : Immunoprecipitation detection diagram of the interaction between endogenous and exogenous proteins AMPK and USP14. A is the immunoprecipitation detection of the interaction between endogenous protein USP14 and AMPK in colorectal cancer cells, and B is the immunoprecipitation detection of the interaction between exogenous protein HA-USP14 and Myc-AMPK α1 and Myc-AMPK α2.
[0021] Figure 3 : Mass spectrometry of USP14 phosphorylation site analysis in the present invention.
[0022] Figure 4 : The antibody affinity purification SDS-PAGE analysis result diagram prepared by the present invention.
[0023] Figure 5 : Graph showing the verification results of the antibody prepared by the present invention specifically recognizing phosphorylation of USP14 Thr52 site. DETAILED DESCRIPTION
[0024] The present invention is described in detail below through examples. It is necessary to point out that the following examples are only used to further illustrate the present invention and cannot be understood as limiting the scope of protection of the present invention. Those skilled in the art can make some non-essential improvements and adjustments to the present invention based on the above-mentioned contents of the present invention.
[0025] Example 1 AMPK modifies USP14 by phosphorylating the threonine site. Regulatory effects: (1) Interaction between endogenous and exogenous proteins AMPK and USP14: In order to clarify the regulatory role between AMPK and USP14, we analyzed the interaction between the two by co-immunoprecipitation: Endogenous: Analysis of the synergistic effect of endogenous AMPK and USP14 in colorectal cancer cells HCT116: 3×10 6HCT116 cells were plated in 60 mm dishes. The next day, 1 mM AMPK activator AICAR and sugar-free induction were added to colorectal cancer cells for 4 hours. The cells were collected and lysed using an appropriate amount of lysis buffer NP-40. Appropriate amounts of protease inhibitors and phosphatase inhibitors were added to each sample. NP-40 buffer: 50 mM Tris-HCl (pH7.4), 150 mM NaCl, 1% NP-40, protease inhibitors and phosphatase inhibitors (NaF and Na3VO4) were added. Incubate on ice for 30 minutes, and vortex gently every 5 minutes. Then centrifuge at high speed (about 12,000-14,000 xg) for 10-15 minutes, collect the supernatant, and incubate the supernatant with Protein A / G magnetic beads (unbound antibodies) at 4°C for 1 hour. Centrifuge to remove the magnetic beads and retain the supernatant.
[0026] Add target antibodies (anti-AMPK, anti-USP14, anti-HA, anti-Myc, anti-p-Thr, and anti-Flag) to the supernatant and incubate overnight (6-8 hours) at 4°C. Add magnetic beads and continue incubation at 4°C for 3-4 hours to ensure that the antibody-antigen complex is bound to the magnetic beads.
[0027] Wash the beads 3-5 times with ice-cold washing buffer (usually a diluted version of lysis buffer). After each wash, separate the beads using a magnetic rack and discard the supernatant. Separate the eluted product on SDS-PAGE and perform Western blotting analysis. Detect the target protein with antibodies to the target protein and antibodies to the co-precipitated protein to observe whether they form a complex.
[0028] Exogenous: We analyzed the interaction between exogenous HA-USP14 and Myc-AMPK α1 and Myc-AMPK α2 by transfection and co-immunoprecipitation: Transfection: Inoculate HEK293T cells in good culture state into culture dishes or multi-well plates, and ensure that the cell confluency is between 40-60% during transfection. Specifically, inoculate about 2-3×10 cells in a 60 mm diameter dish. 6 Add the prepared plasmid DNA-transfection reagent complex to be transfected (the transfection reagent is 250 μL Opti-MEM, 3 μg and 9 μL PEI mixed in sequence) to the cells in the culture dish, shake gently, and culture in a 37°C, 5% CO2 incubator for 4-6 hours, then replace with fresh serum-containing medium and continue to incubate the cells for 24-48 hours.
[0029] Co-immunoprecipitation: Wash the cells with PBA and then lyse the cells with an appropriate amount of lysis buffer NP-40. Add the appropriate amount of protease inhibitors and phosphatase inhibitors to each sample, NP-40 buffer: 50 mM Tris-HCl (pH 7.4), 150 mMNaCl, 1% NP-40, add protease inhibitors and phosphatase inhibitors (NaF and Na3VO4). Incubate on ice for 30 minutes, gently vortex every 5 minutes. Then centrifuge at high speed (about 12,000-14,000 xg) for 10-15 minutes, collect the supernatant, and incubate the supernatant with Protein A / G magnetic beads (unbound antibody) at 4°C for 1 hour. Remove the magnetic beads by centrifugation and retain the supernatant.
[0030] Add target antibodies (anti-AMPK, anti-USP14, anti-HA, anti-Myc, anti-p-Thr, and anti-Flag) to the supernatant and incubate overnight (6-8 hours) at 4°C. Add magnetic beads and continue incubation at 4°C for 3-4 hours to ensure that the antibody-antigen complex is bound to the magnetic beads.
[0031] Wash the beads 3-5 times with ice-cold washing buffer (usually a diluted version of lysis buffer). After each wash, separate the beads using a magnetic rack and discard the supernatant. Separate the eluted products on SDS-PAGE and perform Western blot analysis. Detect the target protein with antibodies to the target protein and antibodies to the co-precipitated protein to observe whether they form a complex.
[0032] like Figure 1 As shown in A, in colorectal cancer cells HCT116, there is a clear interaction between endogenous AMPK and USP14. Similarly, we further used cell transfection and co-immunoprecipitation analysis to find that there is an interaction between exogenous HA-USP14 and Myc-AMPKα1 and Myc-AMPKα2, and the interaction between HA-USP14 and Myc-AMPKα2 is stronger ( Figure 1 B). The above results indicate that there is interaction between endogenous proteins AMPK and USP14, as well as exogenous proteins HA-USP14 and Myc-AMPK.
[0033] (2) AMPK modifies USP14 by phosphorylating the threonine site: AMPK is a key intracellular energy sensor kinase that can regulate the phosphorylation levels of other proteins in the cell. Based on the interaction between AMPK and USP14, we further examined the regulatory effect of AMPK on the phosphorylation level of USP14.
[0034] like Figure 2 As shown in A, immunoprecipitation was performed using phosphorylation antibodies against threonine and AMPK Thr172 (Threonine) sites, and the phosphorylation level of USP14 was detected by Western blotting. It was found that it could precipitate USP14 protein, indicating that AMPK phosphorylates USP14 through the threonine site. Similarly, we transfected HEK293T cells with wild-type kinase AMPK α2 and kinase-inactive mutant AMPK α2 (K45R, lysine 45 mutated to arginine), as shown in Figure 2 As shown in B, AMPK α2 (K45R) transfection failed to phosphorylate USP14 at the threonine site, which proved that AMPK can phosphorylate USP14 at the threonine site.
[0035] Example 2 Identification of novel sites of USP14 phosphorylation by AMPK: 1. In-gel enzymatic digestion The gel strips were obtained by the previous cell transfection and SDS-PAGE electrophoresis, and the gel strips were cut into pieces and destained with 50% acetonitrile containing 50 mM ammonium bicarbonate (NH4HCO3). The gel pieces were dehydrated by incubation with 100% acetonitrile for 5 min, and then the liquid phase in the system was removed, and a dithiothreitol solution with a final concentration of 10 mM was added, and incubated at 37 °C for 60 min. The gel pieces were incubated and dehydrated with 100% acetonitrile again, and iodoacetamide with a final concentration of 55 mM was added after the liquid phase was removed, and incubated at room temperature in the dark for 45 min, and then washed with ammonium bicarbonate with a final concentration of 50 mM, and incubated and dehydrated with 100% acetonitrile again. Finally, the gel pieces were resuspended with 50 mM ammonium bicarbonate containing 10 ng / μL trypsin and incubated on ice for 1 h. After removing the excess solution from the sample, the gel was enzymatically digested overnight at 37°C. The peptides after enzymatic digestion were extracted from the gel using 50% acetonitrile / 5% formic acid and 100% acetonitrile, respectively, and the peptide solution was freeze-dried and then used for later use.
[0036] 2. Liquid chromatography-mass spectrometry analysis The freeze-dried peptides were dissolved in mobile phase A and separated by EASY-nLC 1000 ultra-high performance liquid phase system. The liquid phase gradient was set as follows: 6%-35% B phase from 0 to 22 minutes; 35%-80% B phase from 22 to 26 minutes; 80% B phase from 26 to 30 minutes, and the flow rate was maintained at 500 nL / min. Mobile phase A was an aqueous solution containing 0.1% formic acid and 2% acetonitrile, and mobile phase B was an aqueous solution containing 0.1% formic acid and 90% acetonitrile. After the peptides were separated by the ultra-high performance liquid phase system, they were injected into the NSI ion source for ionization and then into the Thermo Scientific TM Q Exactive TM Plus mass spectrometer.
[0037] The phosphorylation modification sites of USP14 protein were analyzed by combining in-gel enzymatic digestion and high-resolution biomass spectrometry. The mass spectrometry of the identified USP14 phosphorylation sites is shown in Figure 2 Figure 3 One phosphorylation site was identified, and the identification results are shown in Table 1.
[0038] Table 1: Identification of phosphorylation sites of USP14 by high-resolution mass spectrometry
[0039] Note: *The site here refers to the location of the modification in the entire protein sequence From the mass spectrum Figure 3 As shown in the results of Table 1 above, the third amino acid in the USP14 peptide -GGTLKDDDWGNIK-, namely the 52nd threonine in the full sequence of USP14, is phosphorylated.
[0040] In order to further analyze that the identified site is a new phosphorylation site for USP14, we used high performance liquid chromatography (HPLC) and high resolution mass spectrometry (HRMS) to accurately identify and quantitatively analyze the phosphorylated peptides of USP14 at the 52nd threonine site, KGG-pTLKDDDWGNIC and unphosphorylated peptides. The test results are shown in Table 2.
[0041] Table 2: USP14 phosphopeptide quality inspection analysis
[0042] Comparison of the above results showed that this site is a new type of phosphorylation site for USP14, and the obtained phosphorylated polypeptide meets the needs of subsequent antibody preparation.
[0043] Example 3 The preparation of the above-mentioned USP14 Thr52 phosphorylation antibody comprises the following steps: 1. The USP14 phosphorylated peptide "KGG-pTLKDDDWGNIC" was coupled with the abalone highly immunogenic protein (Keyhole Limpet Hemocyanin, KLH) as the USP14 protein phosphorylation antigen; 2. Two female New Zealand white rabbits were immunized with USP14 protein phosphorylated antigen, with 1 mg subcutaneously for the first time, the second time 2 weeks later, and the third time after an interval of 1 week. After the third immunization, blood was collected from the ear vein to test the titer. If the test was unqualified, the fourth immunization was performed and blood was collected again for testing; Antiserum ELISA titer: (1) Design the coated plate according to the experimental needs and mark the well plate; (2) Use CBS coating buffer to dilute USP14 protein phosphorylated antigen to the required concentration, mix well and add to the well plate, 100 μL per well, overnight at 4°C, coating mass: 0.5 ug / well, coating buffer: specifically pH 9.6, 0.05M carbonate buffer; (3) After coating, remove the coating solution, wash the plate three times, add 200 μL of blocking solution to each well, block in a 37°C incubator for 2 h, then remove the ELISA plate, discard the inner solution, and wash the plate three times. The blocking solution is 5% skimmed milk powder dissolved in TBST buffer.
[0044] (4) Antiserum was added at dilutions of 1:1600, 1:3200, 1:6400, 1:12800, 1:25600, 1:51200, 1:102400, 1:204800, and 1:409600, 100 μL per well and incubated in a 37°C incubator for 2 h.
[0045] (5) Take out the ELISA plate, discard the internal solution, wash the plate three times, add 100 μL of diluted ELISA antibody to each well, and incubate at 37°C incubator for 1 h.
[0046] (6) Take out the ELISA plate, discard the internal solution, wash the plate three times, add 200 μL TMB color development solution to each well, and determine the color development time based on the color depth, generally 15 min at 37°C.
[0047] (7) Add 50 μL of 2 M H2SO4 solution to each well to terminate the reaction and read the OD value at 450 nm on a microplate reader. 450 The value is greater than the set negative control OD 450 The dilution corresponding to the well with a value 2.1 times greater than the original value was determined as the titer of the sample. The titer results are shown in Table 3.
[0048] Table 3: Antiserum ELISA titer detection
[0049] It can be seen that the antibody titer is 1:12800, which meets the requirements of subsequent experiments.
[0050] 3. Purification of antibodies: 3.1 Reagents used: NHS Focurose 4FF medium (Weiqi Technology) Prestained marker (purchased from ThermoFisher) Solution A: 0.2M NaHCO3, 0.5M NaCl, pH 8.3 Solution B: 0.5M ethanolamine, 0.5M NaCl, pH 8.3 Solution C: 0.1M sodium acetate, 0.5M NaCl, pH 4.0 Solution D: 20% anhydrous ethanol, prepared with PBS Other reagents were of domestic analytical grade 3.2 Purification steps: After the antiserum ELISA titer test was verified to be qualified, all the serum of female New Zealand white rabbits immunized with USP14 antigen was purified by antigen-antibody affinity chromatography to obtain the target antibody: (1) Preparation of antigen affinity column The unphosphorylated USP14 polypeptide "KGGTLKDDDWGNIC" and the USP14 phosphorylated polypeptide "KGG-pTLKDDDWGNIC" were added to solution A for storage; Take 2 mL of NHS Focurose 4FF medium and put it into a sand core funnel of corresponding specifications to drain. Add 2 times the volume of pre-cooled 0.001M HCl, stir evenly and drain, repeat twice, transfer the medium to the reactor, add the peptide "KGGTLKDDDWGNIC" and phosphorylated peptide "KGG-pTLKDDDWGNIC" to be coupled stored in solution A, stir at room temperature for 2 hours, then transfer to a sand core funnel to drain, and save the coupled solution in the collection container. Add 2 times the volume of medium B solution to the solution, stir evenly and drain, repeat twice, then add 2 times the volume of medium B solution, stir at room temperature for 2 hours, then drain, then add 2 times the volume of medium C solution, stir evenly and drain, repeat twice, then add 2 times the volume of medium D solution, stir evenly and drain, repeat twice, finally add an equal volume of D solution to store, and prepare non-phosphorylated peptide coupling filler and phosphorylated peptide coupling filler respectively; (2) Affinity purification Place the coupled filler in a 4°C display cabinet, balance it with 5 times the volume of the chromatography column (0.15 M NaCl, 20 mM Na2HPO4, pH 7.0), so that the filler is in the same buffer system as the target antibody, repeat 2-3 times, load the sample into the balanced empty chromatography column, incubate for 5 minutes, collect the effluent, repeat the loading 3 times, use 10 times the column volume of Washbuffer (0.15 M NaCl, 20 mM Na2HPO4, pH 7.0) to remove impurities and elute, remove non-specific adsorbed impurities, collect the eluate, elute with 5 times the column volume of Elution buffer (0.1 M glycine, pH 3.0), collect the eluate, and then elute the column with 10 times the column volume of Elution buffer, and collect the eluate. The above loading is specifically to first load the non-phosphorylated peptide coupled filler, collect the effluent, and then load it onto the phosphorylated peptide coupled filler; (3) The eluted antibodies are dialyzed and concentrated by ultrafiltration to obtain non-phosphorylated antibodies and phosphorylated antibodies.
[0051] Detection of the above antibody specifically recognizing the phosphorylation of Thr52 site of USP14: The above antibodies were used to prepare a 12% gel and subjected to SDS-PAGE electrophoresis to analyze the purified antibodies. After the electrophoresis was completed, the gel was taken out and placed in Coomassie Brilliant Blue staining solution (the staining time is usually 30 minutes to 1 hour), and destained with water or decolorizing solution (methanol: acetic acid: water = 4:1:5) until the background was transparent and the protein bands were clearly visible. The results are as follows Figure 4 As shown (M: protein standard; 1: antibody before loading; 2: effluent after loading; 3-9: antibody after elution and purification), after antigen-antibody affinity chromatography, the eluted purified antibody tubes 5-7 can be used for subsequent research.
[0052] Example 4 The purified USP14 Thr52 phosphorylation site polyclonal antibody was validated and applied for testing: In order to prove that the above antibody can specifically recognize AMPK kinase and phosphorylate USP14 through the 52nd threonine site in USP14, 3×10 6 HCT116 cells were plated in 60 mm dishes, and the next day, 1 mM AMPK activator AICAR, 1 μM AMPK inhibitor Compound C, and sugar-free induction were added to treat colorectal cancer cells for 4 hours. Then the cells were collected and lysed, the protein concentration was determined by BCA method, SDS-PAGE and Western blotting were performed, and the purified polyclonal antibody that specifically recognized the USP14 Thr52 site was used as the primary antibody to verify the phosphorylation level of this site.
[0053] Verification results such as Figure 5 As shown in A, AICAR and sugar-free induction significantly promoted the phosphorylation of AMPK Threonine 172, activated AMPK, and significantly increased the phosphorylation level of USP14 Thr52, while Compound C significantly inhibited AMPKThr172 phosphorylation and further reduced the phosphorylation level of USP14 Thr52. This shows that the USP14Thr52 site polyclonal antibody prepared by the present invention can recognize the phosphorylation of Thr52 site in USP14.
[0054] Similarly, in order to further prove that AMPK can phosphorylate and modify USP14 Thr52, and that the antibody prepared by the present invention can specifically recognize the phosphorylation site of USP14 Thr52 by AMPK, we mutated the threonine at position 52 of USP14 to alanine (T52A) by point mutagenesis technology to obtain the mutant Flag-USP14 (T52A); secondly, the wild-type Flag-USP14 (1.5 μg) and empty load (1.5 μg), the mutant Flag-USP14 (T52A) and empty load (1.5 μg), the wild-type Flag-USP14 (1.5 μg) and Myc-AMPK α2 (1.5 μg), the mutant Flag-USP14 (T52A) (1.5 μg) and Myc-AMPK HEK293T cells were transfected with α2 (1.5 μg) plasmid in four groups for 48 hours, and then treated with sugar or without sugar for 4 hours. Subsequently, immunoprecipitation was performed using anti-Flag antibody, and Western blotting was performed using anti-p-USP14 (Thr52) site polyclonal antibody to confirm that Thr52 in USP14 is its phosphorylation site.
[0055] The results are as follows Figure 5 As shown in B, AMPK overexpression promotes phosphorylation of USP14 Thr52 site, but cannot phosphorylate the mutant Flag-USP14 (T52A). The above results show that USP14 is a new substrate of AMPK, AMPK phosphorylates USP14 through the Thr52 site, and the USP14 Thr52 site polyclonal antibody prepared by the present invention can recognize the phosphorylation of the Thr52 site in USP14, which proves that the antibody can be used for future research on the function and molecular mechanism of USP14, and can be used as a marker tool for AMPK kinase activity and phosphorylation modification of USP14.
Claims
1. A phosphorylated antigen peptide at Thr52 of USP14, characterized in that: The active amino acid sequence of the antigen peptide comprises a peptide segment of 14 amino acids, specifically KGG-pTLKDDDWGNIC, wherein threonine (T) is phosphorylated, specifically the 52nd threonine site of the USP14 protein.
2. The Thr52 phosphorylated antigen peptide of USP14 according to claim 1, characterized in that: The phosphorylation is carried out by using AMPK kinase to phosphorylate the 52nd threonine site of USP14.
3. Use of the USP14 Thr52 phosphorylated antigen peptide as claimed in claim 1 or 2 in the preparation of a preparation for specifically recognizing the phosphorylation of USP14 protein Thr52.
4. An antibody that recognizes phosphorylation at Thr52 of USP14, which is prepared by immunizing an animal with the phosphorylated antigen peptide KGG-pTLKDDDWGNIC according to claim 1.
5. A method for preparing an antibody against phosphorylation of Thr52 of USP14, characterized in that: The steps include: (1) Using glutaraldehyde as a coupling agent, the synthesized USP14 phosphorylated antigen peptide was conjugated with the carrier protein abalone highly immunogenic protein (KLH) as an antigen; (2) Immunizing animals with the antigens in step (1) and collecting antiserum; (3) The antiserum is chromatographed and eluted to purify the antibody.
6. The method for preparing an antibody against phosphorylation of Thr52 of USP14 according to claim 5, characterized in that: The animal immunization is to immunize two female New Zealand white rabbits with the antigen coupled in step (1), specifically, the first subcutaneous immunization is 1 mg, the second immunization is 2 weeks later, and the third immunization is 1 week later. After the immunization, blood is collected from the ear vein to test the titer. If the test is unqualified, the fourth immunization is continued, and blood is collected again for testing to obtain qualified antiserum.
7. The method for preparing an antibody against phosphorylation of Thr52 of USP14 according to claim 5 or 6, characterized in that: The purification in step (3) is to couple the antiserum sample with NHS Focurose 4FF medium as filler, and purify it by chromatography. Specifically, the filler is added to the chromatography column, and then 5 times the volume of the balancing solution of the chromatography column is added for balancing, so that the medium is in the same buffer system as the coupled antibody, and the process is repeated 2-3 times. The sample is loaded into the balanced chromatography column, incubated for 5 minutes, the effluent is collected, and the loading is repeated 3 times. The balancing solution is composed of 0.15 M NaCl and 20 mM Na2HPO4, and the pH of the balancing solution is 7.
0.
8. Use of the USP14 Thr52 phosphorylation antibody prepared according to the method of claim 7 in the preparation of a preparation for detecting the phosphorylation of USP14 protein Thr52.
9. A preparation for specifically recognizing phosphorylation of Thr52 site of USP14, characterized in that: The invention comprises the antibody according to claim 3 which specifically recognizes the phosphorylation of Thr52 site of USP14.
